{"id":14229,"date":"2023-09-06T21:30:00","date_gmt":"2023-09-06T13:30:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14229"},"modified":"2024-11-22T21:40:33","modified_gmt":"2024-11-22T13:40:33","slug":"bristol-myers-squibb-acquires-rights-to-zenas-biopharmas-obexelimab-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14229","title":{"rendered":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases"},"content":{"rendered":"\n

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY<\/a>) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas’s obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement, Zenas may receive additional payments linked to the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future net sales of obexelimab in the licensed territories. BMS will gain exclusive rights to develop and commercialize obexelimab in these regions and is also making an equity investment in Zenas.<\/p>\n\n\n\n

Obexelimab’s Potential in Autoimmune Disease Treatment<\/strong>
Obexelimab is an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that targets CD19 and Fc\u03b3RIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. It is currently under study as a subcutaneous injection in a global Phase III trial for patients with IgG4-Related Disease (IgG4-RD), a condition for which there are no approved treatments. Additionally, obexelimab is being investigated in a global Phase II\/III trial for patients with warm antibody Auto-Immune Hemolytic Anemia (wAIHA).-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,429,428,28,849,2271],"class_list":["post-14229","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-auto-immune","tag-bms","tag-bristol-myers-squibb","tag-multi-specific-antibodies","tag-nyse-bmy","tag-zenas-biopharma"],"yoast_head":"\nBristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas's obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement, Zenas may receive additional payments linked to the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future net sales of obexelimab in the licensed territories. BMS will gain exclusive rights to develop and commercialize obexelimab in these regions and is also making an equity investment in Zenas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14229\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14229\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-06T13:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-22T13:40:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases\",\"datePublished\":\"2023-09-06T13:30:00+00:00\",\"dateModified\":\"2024-11-22T13:40:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"BMS\",\"Bristol-Myers Squibb\",\"Multi-specific antibodies\",\"NYSE: BMY\",\"Zenas BioPharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14229#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14229\",\"name\":\"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-06T13:30:00+00:00\",\"dateModified\":\"2024-11-22T13:40:33+00:00\",\"description\":\"US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas's obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement, Zenas may receive additional payments linked to the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future net sales of obexelimab in the licensed territories. BMS will gain exclusive rights to develop and commercialize obexelimab in these regions and is also making an equity investment in Zenas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14229\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14229#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas's obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement, Zenas may receive additional payments linked to the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future net sales of obexelimab in the licensed territories. BMS will gain exclusive rights to develop and commercialize obexelimab in these regions and is also making an equity investment in Zenas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14229","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14229","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-06T13:30:00+00:00","article_modified_time":"2024-11-22T13:40:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14229#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14229"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases","datePublished":"2023-09-06T13:30:00+00:00","dateModified":"2024-11-22T13:40:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14229"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","BMS","Bristol-Myers Squibb","Multi-specific antibodies","NYSE: BMY","Zenas BioPharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14229#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14229","url":"https:\/\/flcube.com\/?p=14229","name":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma's Obexelimab for Autoimmune Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-06T13:30:00+00:00","dateModified":"2024-11-22T13:40:33+00:00","description":"US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation agreement with Zenas BioPharma, investing USD 50 million for development and commercial rights to Zenas's obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia. Under the terms of the agreement, Zenas may receive additional payments linked to the achievement of specific development, regulatory, and commercial milestones, as well as royalties on future net sales of obexelimab in the licensed territories. BMS will gain exclusive rights to develop and commercialize obexelimab in these regions and is also making an equity investment in Zenas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14229#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14229"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14229#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14229"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14229\/revisions"}],"predecessor-version":[{"id":14231,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14229\/revisions\/14231"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}